about
Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancerStructural characterization of the human androgen receptor ligand-binding domain complexed with EM5744, a rationally designed steroidal ligand bearing a bulky chain directed toward helix 12Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomesSafety of antiandrogen therapy for treating prostate cancer.Green tea polyphenols induce p53-dependent and p53-independent apoptosis in prostate cancer cells through two distinct mechanismsAptamer-conjugated nanorods for targeted photothermal therapy of prostate cancer stem cells.Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancerAndrogen receptor activity is affected by both nuclear matrix localization and the phosphorylation status of the heterogeneous nuclear ribonucleoprotein K in anti-androgen-treated LNCaP cells.Hormonal therapy in metastatic prostate cancer: current perspectives and controversiesStructure-based virtual screening and identification of a novel androgen receptor antagonist.Androgen deprivation therapy: past, present and future.Radiotherapy in the management of prostate cancer after radical prostatectomy.Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.Beyond the limits of oxygen: effects of hypoxia in a hormone-independent prostate cancer cell line.Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.Current standards and future directions for prostate cancer radiation therapy.Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines.Experience with degarelix in the treatment of prostate cancer.Targeting the androgen receptor in triple-negative breast cancer: current perspectives.Micellar delivery of flutamide via milk protein nanovehicles enhances its anti-tumor efficacy in androgen-dependent prostate cancer rat model.Differential expression of AP-1 transcription factors in human prostate LNCaP and PC-3 cells: role of Fra-1 in transition to CRPC status.
P2860
Q24193722-188EA7B4-EC00-4F71-ACBC-21C42C2A44E8Q27647445-E216F577-F7E3-492B-A7EB-59706B972EBAQ28385758-8635E183-C66B-4AFF-BEB0-0AB2FC7CCEE5Q33890406-85A5AB8E-EF20-497B-A973-C3E2D29242A8Q34441134-3F8B536F-8109-4A14-9AB4-3C268BC0886DQ34534169-852B931D-AEE4-4C1C-BD71-4CD1AFFD9B2AQ34767644-45A2FD9E-1231-4BFB-B855-ECA208CABA10Q34996358-52AA1ABB-3F8C-4A68-8C3F-D05877DDD0CBQ35043757-47BA4BC6-3465-42AF-86F4-A32F9025E831Q35569303-98CC1E70-7AAD-4EBF-8446-6AA8AA732B4EQ36216496-0EA6E58B-F52D-44DD-9540-6584D8EE1168Q38016530-517E28AD-7B2C-40A2-BA30-9D596D30FEBFQ38104412-51A529B9-189B-4EA2-9449-11059CAB5B46Q38353828-30ABDA94-410E-4937-9704-DA083C30DE5EQ38803264-A039E634-15F7-4ACD-865C-F354360AE04CQ39069174-8E2859C2-A71D-43F1-B39E-1E02DB476A3BQ39431280-A9E8C14D-BEE6-4091-83E9-071718672583Q39499604-3FFAAB09-1B67-4915-B116-7F5BE0DFF4D8Q39591979-0F8E6B89-B83C-4308-A07D-62701828040FQ42029952-7746367C-64F1-4E2D-A493-850E7E84644CQ42364449-BAA4F6E4-1366-430C-B6C4-290CEDC2597DQ43700837-7F8B274A-7B6A-4C14-B003-0CB2B006D33AQ51067963-66C3F9B9-8F18-49D6-9655-A6FB751328AA
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Antiandrogens in the treatment of prostate cancer.
@ast
Antiandrogens in the treatment of prostate cancer.
@en
Antiandrogens in the treatment of prostate cancer.
@nl
type
label
Antiandrogens in the treatment of prostate cancer.
@ast
Antiandrogens in the treatment of prostate cancer.
@en
Antiandrogens in the treatment of prostate cancer.
@nl
prefLabel
Antiandrogens in the treatment of prostate cancer.
@ast
Antiandrogens in the treatment of prostate cancer.
@en
Antiandrogens in the treatment of prostate cancer.
@nl
P2093
P1433
P1476
Antiandrogens in the treatment of prostate cancer.
@en
P2093
Manfred P Wirth
Michael Froehner
Oliver W Hakenberg
P304
306-13; discussion 314
P356
10.1016/J.EURURO.2006.08.043
P407
P577
2006-09-11T00:00:00Z